Venetoclax and Obinutuzumab May Benefit CLL Patients With Complex Karyotype
Patients with CLL who have complex karyotype appear to have better clinical outcomes with venetoclax and obinutuzumab compared with chlorambucil and obinutuzumab.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Machine Learning Identifies Newly Diagnosed CLL Patients at Risk for Certain Outcomes
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Survival Trends With Chronic Lymphocytic Leukemia Over 28 Years in the Netherlands
Relative survival rates were found to improve for all patient age groups over time, although excess mortality persisted to some degree.
Acalabrutinib With Obinutuzumab May Be Safe, Effective in Chronic Lymphocytic Leukemia
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Prognostic Value of Altered Signaling Pathways in Chronic Lymphocytic Leukemia
Mutations were found in 70% of patients, with 53% of patients possessing driver mutations and 17 genes showing mutations in more than 2% of patients.
Ofatumumab May Prolong Survival in Relapsed Chronic Lymphocytic Leukemia
Median progression-free survival was 34.2 months in patients who received ofatumumab and 16.9 months in patients who received no additional treatment.
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Study Finds Real-World Outcomes Differ for Idelalisib in FL and CLL
The analysis revealed that Medicare beneficiaries had different treatment outcomes compared with the trial participants.
Real-World Data Show Higher Economic, AE Burden of CLL
Addressing increased adverse events could be unmet medical need for Medicare-aged patients.
Real-World Sequence Patterns of Novel Agents in CLL Described
More than half of the patients with CLL included in the retrospective study first received a novel agent in the second-line setting.
High Rates of Undetectable MRD Following 2 Years of Ibrutinib-Venetoclax in Certain Patients With CLL/SLL
There is an increasing focus on using the achievement of undetectable MRD in bone marrow as a clinical trial end point in patients with CLL.
Promising Early Results for the Combination of Acalabrutinib, Obinutuzumab, and Venetoclax in Treatment-Naive CLL
An earlier study of obinutuzumab + venetoclax in combination with ibrutinib in patients with CLL showed high rates of diarrhea, bruising, and infusion-related reactions.
Early Look at the Feasibility and Safety of a Third-Generation Anti-CD19 CAR-T Therapy
A third-generation anti-CD19 CAR-T cell therapy showed no major safety concerns and early signs of clinical activity for patients with lymphoid malignancies.
Calquence Approved for Chronic Lymphocytic Leukemia
The FDA has approved Calquence (acalabrutinib; AstraZeneca) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
Monitoring Weight in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Patients receiving ibrutinib for chronic lymphocytic leukemia experienced an average weight gain of 2.4 kg at 1 year after therapy initiation.
Biosimilar Truxima Now Available for Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Single-Cell RNA Sequencing Characterizes T-Cell Impairment in CAR-T Cells Derived From Patients With CLL
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
BTK Inhibition Could Result in Early Risk for Infections
The risk may be transient, as immune function recovered in late phases of treatment.
Adherence to Other Oral Medications Declines Following Introduction of Oral Oncolytics
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
Risk of Second Primary Malignancy After Chronic Lymphocytic Leukemia
The risk for second primary malignancy appeared to increase over time in survivors of chronic lymphocytic leukemia compared with the general population.
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
